retatrutide clinical trial phase retatrutide Weight Loss Treatment Explained retatrutide clinical trials phase approval:

Human evidence is limited to early-phase ulcerative colitis trial work under the PL 14736 designation

The redox sensor KEAP1 facilitates adaptation of T cells to chronic antigen stimulation by preventing hyperactivation

The most commonly reported adverse effects in the Phase 2 trial included: Nausea the most prevalent side effect, particularly during dose escalation Vomiting Diarrhoea Constipation Decreased appetite (which, whilst contributing to weight loss, can be uncomfortable) Eructation (belching) Injection-site reactions (such as redness, bruising, or discomfort at the injection site) These effects are typically mild to moderate in severity and tend to be most pronounced during the first few weeks of treatment or following each dose increase

These mixed findings emphasize that population-level benefits may not be uniformly observed and that precision-nutrition approaches, accounting for genetics, metabolic phenotype, and gut microbiome, are needed to identify subgroups most likely to respond